Cellectis ADRALCLS
Price$1.40

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $72.9M+75.8% YoYTTM through 31 Dec 2025
Net Income -$67.6MTTM through 31 Dec 2025
Free Cash Flow -$41.8MTTM through 31 Dec 2025

Margins

Current
EBITDA Margin-35.0%
Operating Margin-41.6%
Net Margin-92.7%

Returns

-89.1%ROE
-20.8%ROA

Balance Sheet Health

Debt / Equity1.32x
Current Ratio1.52x
Net Debt-$106.6Mnet cash position
Cash & Equivalents$61.5M

Quality Metrics

Piotroski F-Score2 / 9
FCF Margin-57.2%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $72.9M
Diluted EPS
'19'20'21'22'23'24'25
FY2025: $-0.67

Dividend

No dividend

Capital Allocation

Capex Intensity3.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.